Osteoprotegerin (OPG) was a gift from Sankyo Pharmaceutical (Tokyo, Japan), and etanercept was purchased from Takeda Pharmaceutical (Tokyo, Japan). == Culture system for osteoclastogenesis in the absence of osteoblasts == Human peripheral Nicotinuric acid blood was from the buffy coating fraction from healthy volunteers (Japanese Red Cross Society, Tokyo, Japan) after this study had been approved by the Institutional Review Table. ng/ml IL-23. The inductive effect of IL-17 and the inhibitory effect of IFN-gamma on osteoclastogenesis indicate that the balance of these two cytokines is particularly important. We also shown that IL-23 given at a later on stage significantly reduced paw volume in rats with collagen-induced arthritis, inside a dose-dependent manner. Furthermore, anti-IL-23 antibody reduced synovial cells swelling and bone damage in these rats. These findings suggest that IL-23 is important in human being osteoclastogenesis and that neutralizing IL-23 after onset of collagen-induced arthritis has restorative potential. Thus, controlling IL-23 production and Rabbit polyclonal to DARPP-32.DARPP-32 a member of the protein phosphatase inhibitor 1 family.A dopamine-and cyclic AMP-regulated neuronal phosphoprotein. function could be a strategy for avoiding swelling and bone destruction in individuals with rheumatoid arthritis. == Intro == Rheumatoid arthritis is a chronic inflammatory disease characterized by the damage of articular cartilage and bone [1]. Our group and another have recognized osteoclasts in synovial cells [2] and eroded bone surfaces [3], suggesting that osteoclastic bone resorption is involved in the pathogenesis of rheumatoid arthritis (RA). Furthermore, levels of inflammatory cytokines such as TNF-, IL-6, and IL-1 are elevated in synovial fluids of individuals with RA [4,5], and the cytokines promote bone resorption by inducing the differentiation or activation of osteoclasts [2,6,7]. It is well known that attenuating the activity of inflammatory cytokines in individuals with RA inhibits bone resorption and damage. IL-23, which was recently identified as a heterodimeric, proinflammatory cytokine and new member of the IL-12 family [8], is definitely secreted by antigen-presenting cells. IL-23 is composed of p19 and p40 subunits and shares a common p40 subunit with IL-12 [8]. IL-23 signals through the IL-23 receptor complex, which is composed of the IL-12 receptor chain and the IL-23 receptor [9]. IL-23 was initially described as a cytokine able to induce the manifestation of IFN- in human being CD45RO-positive (memory space) T cells and to activate memory space T cells to secrete inflammatory cytokines including IFN- and IL-17 [8,10]. Furthermore, it is reported that recombinant human being (rh)IL-23 upregulates the production of IFN-, IL-17, and IL-10 in triggered human being nave T cells [11]. In models of T helper type 1 (Th1) differentiation of human being T cells, it was initially proposed that IL-23 functions later on than IL-12 and maintains Th1 commitment by its preferential action on memory space T cells [12-14]. In animal studies, it is reported that IL-23-deficient (IL-23 p19-/-) mice are resistant to experimental autoimmune encephalomyelitis (EAE), whereas IL-12 (p35)-deficient mice are still susceptible to swelling [15]. Murphy and colleagues reported that mice with collagen-induced arthritis (CIA) and Nicotinuric acid IL-23 deficiency (IL-23 p19-/-) are completely resistant to the development of joint and bone pathology and that IL-23 is required for the induction of joint inflammatory mediators including IL-17 and TNF- [16]. Furthermore, transgenic mice constitutively overexpressing IL-23 p19 develop spontaneous severe multi-organ swelling with elevated levels of TNF- [17]. These findings suggest that IL-23 has a pivotal part in the establishment and maintenance of inflammatory autoimmune diseases. In addition, some reports have established the idea of a critical function for the IL-23IL-17 pathway in some autoimmune diseases and emphasize the importance of understanding the origins of development of IL-17 effector cells [10,18]. IL-17 is a proinflammatory cytokine secreted by triggered T cells [19] or neutrophils [20]. We have reported that IL-17 levels in synovial fluids are significantly higher in individuals with RA than in individuals with osteoarthritis and that IL-17 stimulates osteoclast differentiation by inducing the manifestation of receptor activator of NF-B ligand (RANKL) via a mechanism involving the synthesis of prostaglandin E2in osteoblastsin vitro[21]. In addition, we reported that IL-17 directly stimulates human being osteoclastogenesis from human being monocytes only, Nicotinuric acid via the TNF- or RANKRANKL pathway [22]. Recently, some groups possess reported that IL-17 is also important in joint damage in animal models and in individuals with RA [23-25]. It is therefore indicated that IL-23 is definitely involved in osteoclastic bone resorption, at least in part via the IL-17 pathway, and that IL-23 is important in the progression of arthritis. However, the direct effect of IL-23 on human being osteoclastogenesis from peripheral blood mononuclear cells (PBMC) and the part of anti-IL-23 antibody in CIA in rats remain unclear. In the present study we.